3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow Peyronie's Disease: new trials by email Literature Review of Peyronie's Disease trials Research Report on Peyronie's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease AA4500 - Peyronie's Disease | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 20 | 2011-09-01 | 2017-10-05 |
| H-22411: BOTOX® for Peyronie's Disease 100 units of Botulinum Toxin Type A, Preservative free normal saline, 100 units Botulinum Toxin A - Peyronie's Disease | Phase 2 | Completed | Mohit Khera | 12 | 2009-08-07 | 2024-04-08 |
| The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease AA4500, Placebo - Peyronie's Disease | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 147 | 2008-08-01 | 2017-10-05 |
Connective Tissue Diseases (3) · Genital Diseases (3) · Genital Diseases, Male (3) · Male Urogenital Diseases (3) · Penile Diseases (3) · Skin and Connective Tissue Diseases (3) · Urogenital Diseases (3)
Botulinum Toxins, Type A (1) · Crossing Over, Genetic (1) · Injections (1) · Microbial Collagenase (1) · xiapex (1)
Endo USA Inc., a Keenova Therapeutics Company (2) · Mohit Khera (1)
United States (3)
Gregory J. Kaufman, MD (1) · Mohit Khera, MD, MBA (1) · Veronica Urdaneta, MD (1)